tradingkey.logo

Sanara Medtech Inc

SMTI
查看詳細走勢圖
20.240USD
+0.200+1.00%
收盤 02/06, 16:00美東報價延遲15分鐘
180.76M總市值
虧損本益比TTM

Sanara Medtech Inc

20.240
+0.200+1.00%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.00%

5天

-8.00%

1月

-19.27%

6月

-18.39%

今年開始到現在

-13.32%

1年

-41.76%

查看詳細走勢圖

TradingKey Sanara Medtech Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Sanara Medtech Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業中等水平。增長潛力很大。當前估值合理,在藥品行業排名84/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為40.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Sanara Medtech Inc評分

相關信息

行業排名
84 / 159
全市場排名
226 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Sanara Medtech Inc亮點

亮點風險
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
業績高增長
公司營業收入穩步增長,連續3年增長89.06%
業績增長期
公司處於發展階段,最新年度總收入86.67M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入86.67M美元
估值高估
公司最新PE估值-4.65,處於3年歷史高位
機構減倉
最新機構持股1.18M股,環比減少1.80%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉183.14K股

分析師目標

基於 2 分析師
買入
評級
40.000
目標均價
+97.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Sanara Medtech Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Sanara Medtech Inc簡介

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
公司代碼SMTI
公司Sanara Medtech Inc
CEOMuppalla (Suresh V)
網址https://sanaramedtech.com/
KeyAI